Business Imperatives

  • A France-based biopharmaceutical company wanted support for Manuscript preparation and publication. 
  • They approached Freyr to develop a strong study design and prepare a manuscript for a product with multiple add-on therapy indications. 

Objectives

To source validated clinical manuscripts for publication in a high-impact journal with a global reach. The focus was on the therapeutic area of Hematology/Anti-thrombotic therapies.

Problem Statement

  • Unavailability of clinical literature. 
  • Challenges were encountered in framing a robust study design. 
  • The randomized, double-blind, multicenter, parallel-group, phase IIb trial posed a roadblock for the client. 
  • Difficulties arose in manuscript preparation due to multiple and add-on therapy indications. 

Freyr Solutions and Services

Freyr Solutions and Services
  • Ensured identification and selection of a reputable journal with a high impact factor (I.F.). 
  • Successfully prepared and published the manuscript. 
  • Ensured compliance with Regulatory guidelines throughout the manuscript preparation and publication process. 
  • Addressed reviewer comments effectively, ensuring the manuscript met rigorous publication standards. 
  • Freyr developed a scientifically validated clinical manuscript, ensuring compliance with ICMJE, GPP3, COPE, and EQUATOR guidelines. 
  • The manuscript was structured according to trail-based standards, adhering to standard guidelines. 
  • Additionally, Freyr supported the client in selecting a reputable journal with a decent impact factor, facilitating manuscript publication, and addressing reviewer comments.  
  • Streamlined publication processes significantly. 
  • Implemented cost-effective solutions with quick turnaround times
  • End-to-end publication support. 

Freyr successfully prepared the manuscript tailored to the therapeutic area of Hematology/Anti-thrombotic therapies. This manuscript met the stringent standards required for publication in a high-impact journal with a global readership, fulfilling the specific needs of the France-based biopharmaceutical company.